Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 2,12 € (+606,67 %). La mediana es de 1,82 € (+506,67 %).
| Comprar |
6 |
| Mantener |
0 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Tenaya Therapeutics receives RMAT designation for gene therapy TN-401
The FDA has granted RMAT designation to Tenaya Therapeutics' AAV9-based gene therapy TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy. The decision is based on interim RIDGE-1 Phase 1b/2 data showing lower rates of premature ventricular contractions and non-sustained ventricular tachycardias. TN-401 already had Fast Track and orphan drug status; the RMAT designation enables expanded interactions with the FDA and may open accelerated approval pathways. Tenaya plans to present additional RIDGE-1 data and an update on regulatory plans for a pivotal trial in Q4 2026. » Más en de.investing.com
Tenaya presents promising gene therapy data and cites liquidity through Q3 2027
At an investor conference, Tenaya reported positive early efficacy and safety data for its three clinical programs: TN-201 showed sustained improvements in six evaluable patients up to two years after a single dose, TN-401 reduced premature ventricular contractions by a median of 64%, and TN-301 is being readied for Phase II. Management is working on dose selection, regulatory alignment and development plans and expects clarity by the end of 2024. Tenaya reports cash runway through the third quarter of 2027, stressing that this provides time for several clinical and regulatory milestones before additional financing would be needed. » Más en de.investing.com
Tenaya Therapeutics expects regulatory clarity and funding needs in fourth quarter
At the Canaccord Growth Conference, Tenaya reported positive early safety and efficacy signals for gene therapies TN-201 and TN-401 and the reactivation of the small‑molecule program TN-301. Regulatory decisions on the design of approval‑relevant studies for TN-201 and TN-401, as well as details on TN-301, are expected in the fourth quarter and will determine further capital allocation. The company noted cash of roughly $78 million, expected to last into the third quarter of 2027, but stressed that additional financing will be required for the planned registration and Phase II studies. » Más en de.investing.com
Tenaya reports positive interim results for gene therapy TN-401 in ARVC
Tenaya presented interim results from the phase 1b/2 RIDGE‑1 study: in six patients a single infusion of TN‑401 led to a mean reduction in premature ventricular contractions of about 60–67% and the treatment was reported to be well tolerated. Biopsies showed presence of TN‑401 DNA and stable to slightly improved PKP2 protein levels; common adverse events were transient increases in troponin or transaminases. The EMA has granted TN‑401 PRIME status. Financial analyses highlight stronger liquidity than debt but note negative free cash flow, while analyst price targets range between $2 and $8. » Más en de.investing.com
Tenaya Therapeutics receives Nasdaq warning over minimum share price and boosts stock plan
Tenaya Therapeutics received a warning from Nasdaq because the closing price was below $1.00 for 30 consecutive trading days; the company has until July 27, 2026 to raise the price to $1.00 or more for at least ten trading days. The board increased the shares reserved for the 2024 Inducement Equity Incentive Plan by 2,161,000 to a total of 3,361,000 shares. At the same time, Tenaya plans a $60 million capital raise (50 million units at $1.20) and announced that the FDA lifted the clinical hold on the MyPEAK-1 study of TN-201; interim results from the Phase 1b RIDGE-1 study were also released, after which analysts lowered their price targets but maintained buy ratings. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 1,5 M | - |
| Beneficio bruto | 1,5 M | - |
| Beneficio neto | -16,72 M | 3,23 % |
| EBITDA | -16,26 M | 3,67 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 72,41 M € |
Número de acciones | 227,93 M |
Máximo/mínimo de 52 semanas | 1,33 € - 0,27 € |
| Dividendos | No |
Beta | 2,88 |
Ratio P/E | -0,71 |
Ratio PEG | -0,02 |
Ratio P/B | 1,45 |
Ratio P/S | 26,25 |
Perfil de la empresa
Tenaya Therapeutics, Inc., una empresa de biotecnología, descubre, desarrolla y distribuye terapias para las enfermedades cardíacas en Estados Unidos. Desarrolla sus productos mediante plataformas de regeneración celular, terapia génica y medicina de precisión. La compañía está desarrollando TN-201, una terapia génica basada en virus adenoasociados (AAV) para tratar la miocardiopatía hipertrófica genética (gHCM) causada por mutaciones haploinsuficientes en el gen de la proteína C3 de unión a la miosina (MYBPC3); y TN-301, un inhibidor de molécula pequeña de la histona desacetilasa 6 (HDAC6i) para su uso en la insuficiencia cardíaca con fracción de eyección conservada (HFpEF) y la miocardiopatía dilatada genética (gDCM). También desarrolla TN-401, una terapia génica basada en AAV que trata la miocardiopatía arritmogénica del ventrículo derecho genética (gARVC) causada por mutaciones en el gen de la placofilina 2 (PKP2); una terapia génica basada en AAV diseñada para administrar el gen DWORF (dwarf open reading frame) en el corazón para la DCM; y el programa de reprogramación, un enfoque basado en AAV para la regeneración cardíaca que reemplaza las células cardíacas perdidas en pacientes con insuficiencia cardíaca debida a un infarto de miocardio previo. La compañía se fundó en 2016 y tiene su sede en South San Francisco, California.
| Nombre | Tenaya Therapeutics |
| CEO | Faraz Ali |
| Sede | South San Francisco,
ca Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Productos farmacéuticos |
| Salida a bolsa | 30/07/2021 |
| Empleados | 70 |
Deep Dive
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | TNYA |